Voyager Therapeutics (NASDAQ:VYGR) Shares Cross Below 50-Day Moving Average – What’s Next?

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $4.39 and traded as low as $3.97. Voyager Therapeutics shares last traded at $4.00, with a volume of 590,311 shares traded.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Voyager Therapeutics in a report on Wednesday, October 8th. Wall Street Zen upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Wedbush reaffirmed an “outperform” rating and issued a $8.00 price target on shares of Voyager Therapeutics in a report on Tuesday, November 11th. Finally, HC Wainwright cut their price objective on shares of Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, November 12th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $12.15.

Voyager Therapeutics Trading Down 2.9%

The stock has a market cap of $222.40 million, a PE ratio of -1.85 and a beta of 1.23. The business has a 50 day moving average of $4.39 and a 200-day moving average of $3.90.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.06. The business had revenue of $11.15 million during the quarter, compared to the consensus estimate of $7.86 million. Voyager Therapeutics had a negative return on equity of 48.94% and a negative net margin of 404.85%. Research analysts expect that Voyager Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, CFO Nathan D. Jorgensen sold 7,666 shares of Voyager Therapeutics stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $4.78, for a total value of $36,643.48. Following the transaction, the chief financial officer directly owned 123,834 shares in the company, valued at approximately $591,926.52. The trade was a 5.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 6.39% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

Several hedge funds have recently made changes to their positions in VYGR. AQR Capital Management LLC increased its position in Voyager Therapeutics by 179.3% in the 1st quarter. AQR Capital Management LLC now owns 495,260 shares of the company’s stock valued at $1,674,000 after acquiring an additional 317,927 shares during the period. Acadian Asset Management LLC increased its holdings in shares of Voyager Therapeutics by 863.3% in the first quarter. Acadian Asset Management LLC now owns 230,708 shares of the company’s stock valued at $778,000 after purchasing an additional 206,758 shares during the period. Two Sigma Investments LP acquired a new position in shares of Voyager Therapeutics in the third quarter valued at approximately $657,000. Nuveen LLC purchased a new stake in shares of Voyager Therapeutics during the first quarter worth approximately $368,000. Finally, Hsbc Holdings PLC lifted its holdings in shares of Voyager Therapeutics by 118.5% during the second quarter. Hsbc Holdings PLC now owns 148,377 shares of the company’s stock worth $440,000 after purchasing an additional 80,474 shares during the period. Institutional investors and hedge funds own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.